Cours Wayland Group Corp. Canadian Securities Exchange
Actions
WAYL
CA9442041062
Produits pharmaceutiques
CA 2016 | 4,06 5,55 3,69 | CA 2017 | 3,22 4,41 2,93 | Capitalisation | 203 M 278 M 185 M |
---|---|---|---|---|---|
Résultat net 2016 | -8 M -10,94 M -7,27 M | Résultat net 2017 | -67 M -91,64 M -60,85 M | VE / CA 2016 * | - |
Dette nette 2016 | 9,13 12,48 8,29 | Trésorerie nette 2017 | 0,42 0,57 0,38 | VE / CA 2017 | 63 046 727 x |
PER 2016 * |
-
| PER 2017 |
-2,13
x | Employés | - |
Rendement 2016 * |
-
| Rendement 2017 |
-
| Flottant | 100% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Varia. 1 janv. | Capi. | |
---|---|---|
+43,17% | 6,29 Md | |
-14,69% | 4,55 Md | |
-8,17% | 3,23 Md | |
+6,95% | 3,27 Md | |
-1,76% | 2,56 Md | |
+50,20% | 2 Md | |
-7,85% | 1,68 Md | |
-0,40% | 1,64 Md | |
-9,91% | 1,59 Md |